ARGX vs AXSM
argenx SE vs Axsome Therapeutics, Inc. — AI-powered side-by-side comparison
VS
AXSM
Axsome Therapeutics, Inc.
55
Watch
| Metric | ARGX | AXSM |
|---|
| AI Score |
69
|
55
|
| Price |
$864.40
|
$215.92
|
| P/E Ratio |
31.34×
|
-57.54×
|
| ROE |
17.6%
|
-207.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
93.2%
|
| Debt / Equity |
0.01×
|
2.63×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
41.5
|
| Beta |
-0.022
|
0.596
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus AXSM.
ARGX leads by 14 points.
ARGX scores 69/100 (Buy) versus AXSM at 55/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
AXSM Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 20.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 20.4% signals elevated volatility — Risk